Allogeneic cardiosphere-derived cell therapyCapricor Therapeutics

Deramiocel

Deramiocel (CAP-1002) is an allogeneic cardiosphere-derived cell therapy delivered by intravenous infusion. Capricor is developing it to slow the skeletal-muscle and cardiac decline of Duchenne muscular dystrophy.

Also known as: CAP-1002

Forecast a trial in the ArenaBrowse all benchmarks
1
Trials tracked
1
Resolved
1
Indications
0
Targets

Deramiocel forecasting benchmarks

1 benchmark
ResolvedPhase 3

HOPE-3 Phase 3: deramiocel (CAP-1002) Duchenne muscular dystrophy (DMD)

Deramiocel · Duchenne muscular dystrophy

Clinical Trials

Indications studied

Duchenne muscular dystrophy· DMD

Developed by

Capricor Therapeutics· CAPR

About Deramiocel

What is Deramiocel?

Deramiocel (CAP-1002) is an allogeneic cardiosphere-derived cell therapy delivered by intravenous infusion. Capricor is developing it to slow the skeletal-muscle and cardiac decline of Duchenne muscular dystrophy. It is a allogeneic cardiosphere-derived cell therapy developed by Capricor Therapeutics.

What does Deramiocel target?

Deramiocel's mechanism is summarized above; see the linked trial readouts for details.

How well do AI models predict Deramiocel trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.

Keep exploring

All benchmarksDiseasesCompaniesTargets & genes